Novabridge Biosciences ADR
(NBP)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 151,961 | 0 | N/A | 0 | 329,126 |
| Marketable Securities | 55,525 | 0 | N/A | 0 | 80,801 |
| Other current assets | 22,991 | 0 | 0 | 0 | 14,113 |
| TOTAL | $230,477 | $0 | $N/A | $0 | $424,040 |
| Non-Current Assets | |||||
| PPE Net | 204 | N/A | N/A | N/A | N/A |
| Investments And Advances | 19,000 | 0 | 0 | 0 | 1,574 |
| Other Non-Current Assets | 4,146 | 0 | 0 | 0 | 44,541 |
| TOTAL | $23,350 | $N/A | $N/A | $N/A | $46,115 |
| Total Assets | $253,827 | $0 | $N/A | $0 | $484,286 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 0 | N/A | 0 | 4,133 |
| Accounts payable and accrued liabilities | 11,259 | 0 | 0 | 0 | 0 |
| Other current liabilities | 1,976 | 0 | N/A | 0 | 83,541 |
| TOTAL | $13,972 | $0 | $N/A | $0 | $91,442 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 3,222 | 0 | 0 | 0 | 52,603 |
| TOTAL | $3,222 | $N/A | $N/A | $N/A | $52,603 |
| Total Liabilities | $17,194 | $0 | $N/A | $0 | $146,859 |
| Shareholders' Equity | |||||
| Common Shares | 19 | 0 | N/A | 0 | 18 |
| Retained earnings | -1,256,470 | 0 | N/A | 0 | -1,052,907 |
| Other shareholders' equity | 40,079 | 0 | 0 | 0 | 51,572 |
| TOTAL | $236,633 | $0 | $N/A | $0 | $337,427 |
| Total Liabilities And Equity | $253,827 | $0 | $0 | $0 | $484,286 |